To examine the mechanism of low B4GALT1 expression that provides patients with advantages from ACT, we considered that the immune system, in particular the efficient immune cells, has a crucial part in the reaction of bladder cancer to chemotherapy. Here, B4GALT1 is linked to urinary bladder cancer.